Cost-Effectiveness Analysis 2.0

• Published in: The New England journal of medicine Vol. 376; no. 3; pp. 203 - 205
• Main Authors: Neumann, Peter J, Sanders, Gillian D
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 19-01-2017
• Subjects: Cost analysis; Cost-Benefit Analysis - ethics; Cost-Benefit Analysis - methods; Cost-Benefit Analysis - standards; Guidelines as Topic; Health care; Health Care Costs; Health Care Rationing - economics; Health Care Rationing - ethics; Health economics; Humans; Quality-Adjusted Life Years; United States; United States > US
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMp1612619

As prominent groups in U.S. health care ramp up use of cost-effectiveness analysis to measure and communicate the value of new drugs and other interventions, an expert panel has released updated guidelines for such analysis.
Cost-effectiveness analysis in U.S. health care seems poised for a second act of sorts. Although it has never actually gone away, efforts to apply it have encountered resistance, and the federal government and some health care organizations have sometimes prohibited its use or relegated it to a minor role. But several developments are helping to recharge the field. One is the embrace of its methods by prominent groups that are using it to measure and communicate the value of new drugs and other interventions. Another is the publication of new guidelines for such analysis from a national panel that is . . .